Cerevance to Participate in Piper Sandler Virtual CNS Symposium
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative diseases and obesity, today announced participation at the Piper Sandler Virtual CNS Symposium being held from August 14-15, 2025.
Details of the event are as follows:
Q&A Session with Cerevance
- Cerevance Presenters: Craig Thompson, Chief Executive Officer and Rob Middlebrook, Chief Financial Officer
- Date/Time: Thursday, August 14, 2025, 2:30 – 2:55 p.m. ET
- Location: Virtual
About Cerevance
Cerevance is focused on advancing cell type-specific therapies for the treatment of neurodegenerative and central nervous system-controlled metabolic disorders. Our proprietary platform, Nuclear Enriched Transcript Sort sequencing (NETSseq), allows us to identify targets that are expressed at very low levels, that are present in rare cell types, or that change over time as a disease progresses. Our most advanced investigational treatment, solengepras, is currently in Phase 3 development and has the potential to be a first-in-class, oral non-dopaminergic therapy for both motor and non-motor symptoms of Parkinson's disease. Our second investigational therapy, CVN766, is designed to be a highly selective oral antagonist of the orexin 1 receptor for the potential treatment of binge eating disorder and schizophrenia. Our third investigational treatment, CVN293, is a highly selective investigational oral inhibitor targeting potassium two pore domain channel subfamily K member 13 (KCNK13). CVN293 represents a potentially novel intervention point for neurodegenerative disorders and obesity. For more information, please visit www.cerevance.com and follow us on LinkedIn and X.
Contacts
Cerevance:
Johnna Simões, ir@cerevance.com
Media:
April Dovorany, adovorany@realchemistry.com, +1-262-909-8739
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
